Related Experiment Video
Updated: Jul 30, 2026
08:27
The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
Published on: July 25, 2011
20.1K
Mmp-9, a potential target for cerebral ischemic treatment
Xue Dong1, Yu-Ning Song, Wei-Guo Liu
1Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, No. 44 WenHuaXi Road, Jinan 250012, P.R. China.
Current Neuropharmacology
|June 2, 2010
Summary
Matrix metalloproteinase-9 (MMP-9) plays a key role in brain damage after stroke. Drugs targeting MMP-9 show promise in reducing cerebral ischemic injury and improving outcomes.
Area of Science:
- Biochemistry
- Neuroscience
- Pathology
Background:
- Matrix metalloproteinase-9 (MMP-9) is crucial for extracellular matrix remodeling.
- Elevated MMP-9 expression is observed in cerebral ischemia and stroke.
- MMP-9 contributes to matrix degradation, blood-brain barrier disruption, and infarct expansion.
Purpose of the Study:
- To review the physiological characteristics of MMP-9.
- To elucidate the role of MMP-9 in the development and progression of cerebral ischemic diseases.
- To explore therapeutic strategies targeting MMP-9 for stroke treatment.
Main Methods:
- Literature review of studies on MMP-9 in cerebral ischemia and stroke.
- Analysis of research on the involvement of MMP-9 in pathological processes.
- Examination of preclinical and clinical data on MMP-9-targeting drugs.
Main Results:
- MMP-9 is significantly upregulated following cerebral ischemia.
- MMP-9 exacerbates ischemic brain injury by degrading the extracellular matrix and compromising the blood-brain barrier.
- Various drugs, including tetracycline derivatives and ACE inhibitors, can attenuate MMP-9 levels and mitigate ischemic damage.
Conclusions:
- MMP-9 is a critical factor in the pathophysiology of cerebral ischemic diseases.
- Targeting MMP-9 represents a promising therapeutic avenue for stroke.
- Further research into MMP-9 inhibitors could lead to novel treatments for stroke patients.
